News Related to Relapsed or Refractory Marginal Zone Lymphoma

Related coverage linked through entity extraction aliases.

FDA approves Bristol Myers Squibb’s Breyanzi for relapsed or refractory marginal zone lymphoma

May 18, 2026

The FDA approved Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic therapies. In TRANSCEND FL, the CAR T therapy showed a 95.5% overall response rate and 62.1% complete response rate.

Lisocabtagene Maraleucel Shows High Response Rates in Relapsed, Refractory Marginal Zone Lymphoma

Feb 20, 2026

Phase 2 trial data show lisocabtagene maraleucel achieved a 95% overall response rate in patients with relapsed or refractory marginal zone lymphoma, with a manageable safety profile and no new safety signals.